A compound having the structure of Formula: TM-L-AM, wherein TM is a targeting moiety that is an anti-PD-L1 antibody that is a PD-L/PD-1 Axis antagonist, L is a linker, and AM is an activating moiety that is represented by the structure of Formula (Ic): wherein dashed line represents bond or absence of bond, is the point to be connected to the linker; R 1 is -W 0 -W 1 -W 2 -W 3 -W 4; W 0 is a bond, alkyl, alkenyl, alkynyl, alkoxy, or -alkyl-S-alkyl-; W 1 is a bond, -O-, or -NR 2 -, wherein R 2 is hydrogen, alkyl or alkenyl; W 2 is a bond, -O-, -C -, -C -, or -S 2 -; W 3 is a bond, -NR 3 -, wherein R 3 is hydrogen, alkyl or alkenyl; W 4 is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, aryloxy, heteroaryl, or heterocyclyl, each of which is optionally substituted by one or more substituents selected from the group consisting of hydroxyl, alkoxy, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -NH 2, nitro, -alkyl-hydroxyl, -alkyl-aryl, -alkyl-heteroaryl, -alkyl-heterocyclyl, -O-R 4, -O-alkyl-R 4, -alkyl-O-R 4, -C -R 4, -alkyl-C -R 4, -alkyl-C -O-R 4, -C -O-R 4, -S-R 4, -S 2 -R 4, -NH-S 2 -R 4, -alkyl-S-R4, -alkyl-S 2 -R 4, -NHR 4, -NR 4 R 4,-NH-alkyl-R 4, halogen, -CN, -NO 2, and -SH, wherein R 4 is independently hydrogen, alkyl, alkenyl, -alkyl-hydroxyl, aryl, heteroaryl, heterocyclyl, or haloalkyl; Z is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryl, haloalkyl, heteroaryl, heterocyclyl, each of which can be optionally substituted by one or more substituents selected from the group consisting of hydroxyl, alkoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, halogen, cyano, nitro, -N(R 5) 2, -alkoxy-alkyl, -alkoxy-alkenyl, -C -alkyl, -C -O-alkyl, -O-C -alkyl, -C -N(R 5) 2, aryl, heteroaryl, -CO-aryl, and -CO-heteroaryl, wherein each R 5 is independently hydrogen, alkyl, haloalkyl, -alkyl-aryl, or -alkyl-heteroaryl; R is hydrogen, alkyl, alkoxy, haloalkyl, halogen, aryl, heteroaryl, heterocyclyl, each of which is optionally substituted by one or more substituents selected from the group consisting of hydroxyl, alkoxy, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -NH 2, nitro, -alkyl-hydroxyl, -alkyl-aryl, -alkyl-heteroaryl, -alkyl-heterocyclyl, -O-R 4, -O-alkyl-R 4, -alkyl-O-R 4, - C -R 4, -C -NH-R 4, -C -NR 4 R 4, -alkyl-C -R 4, -alkyl-C -O-R 4, -C -O-R 4, -O-C -R 4, -S-R 4, -C -S-R 4, -S-C -R 4, -S 2 -R 4, -NH-S 2 -R 4, -alkyl-S-R 4, -alkyl-S 2 -R 4, - NHR 4, -NR 4 R 4,-NH-alkyl-R 4, halogen, -CN, and -SH, wherein R 4 is independently hydrogen, alkyl, alkenyl, alkoxy, -alkyl-hydroxyl, aryl, heteroaryl, heterocyclyl, or haloalkyl; n is 0, 1, 2, 3, or 4; wherein the AM is capable of binding specifically to human TLR7, TLR8, or TLR7 and TLR8; or a pharmaceutically acceptable salt or solvate thereof. R 1 is -W 0 -W 1 -W 2 -W 3 -W 4; W 0 is a bond, alkyl, alkenyl, alkynyl, alkoxy, or -alkyl-S-alkyl-; W 1 is a bond, -O-, or -NR 2 -, wherein R 2 is hydrogen, alkyl or alkenyl; W 2 is a bond, -O-, -C -, -C -, or -S 2 -; W 3 is a bond, -NR 3 -, wherein R 3 is hydrogen, alkyl or alkenyl; W 4 is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, aryloxy, heteroaryl, or heterocyclyl, each of which is optionally substituted by one or more substituents selected from the group consisting of hydroxyl, alkoxy, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -NH 2, nitro, -alkyl-hydroxyl, -alkyl-aryl, -alkyl-heteroaryl, -alkyl-heterocyclyl, -O-R 4, -O-alkyl-R 4, -alkyl-O-R 4, -C -R 4, -alkyl-C -R 4, -alkyl-C -O-R 4, -C -O-R 4, -S-R 4, -S 2 -R 4, -NH-S 2 -R 4, -alkyl-S-R4, -alkyl-S 2 -R 4, -NHR 4, -NR 4 R 4,-NH-alkyl-R 4, halogen, -CN, -NO 2, and -SH, wherein R 4 is independently hydrogen, alkyl, alkenyl, -alkyl-hydroxyl, aryl, heteroaryl, heterocyclyl, or haloalkyl; Z is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryl, haloalkyl, heteroaryl, heterocyclyl, each of which can be optionally substituted by one or more substituents selected from the group consisting of hydroxyl, alkoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, halogen, cyano, nitro, -N(R 5) 2, -alkoxy-alkyl, -alkoxy-alkenyl, -C -alkyl, -C -O-alkyl, -O-C -alkyl, -C -N(R 5) 2, aryl, heteroaryl, -CO-aryl, and -CO-heteroaryl, wherein each R 5 is independently hydrogen, alkyl, haloalkyl, -alkyl-aryl, or -alkyl-heteroaryl; R is hydrogen, alkyl, alkoxy, haloalkyl, halogen, aryl, heteroaryl, heterocyclyl, each of which is optionally substituted by one or more substituents selected from the group consisting of hydroxyl, alkoxy, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -NH 2, nitro, -alkyl-hydroxyl, -alkyl-aryl, -alkyl-heteroaryl, -alkyl-heterocyclyl, -O-R 4, -O-alkyl-R 4, -alkyl-O-R 4, - C -R 4, -C -NH-R 4, -C -NR 4 R 4, -alkyl-C -R 4, -alkyl-C -O-R 4, -C -O-R 4, -O-C -R 4, -S-R 4, -C -S-R 4, -S-C -R 4, -S 2 -R 4, -NH-S 2 -R 4, -alkyl-S-R 4, -alkyl-S 2 -R 4, - NHR 4, -NR 4 R 4,-NH-alkyl-R 4, halogen, -CN, and -SH, wherein R 4 is independently hydrogen, alkyl, alkenyl, alkoxy, -alkyl-hydroxyl, aryl, heteroaryl, heterocyclyl, or haloalkyl; n is 0, 1, 2, 3, or 4; wherein the AM is capable of binding specifically to human TLR7, TLR8, or TLR7 and TLR8; or a pharmaceutically acceptable salt or solvate thereof.